DULUTH, Ga., Feb. 27, 2019 /PRNewswire/ -- Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that 12-month data from its real-world study in Europe evaluating Sebacia Microparticles for treatment of facial acne will be presented during the American Academy of Dermatology (AAD) 2019 Annual Meeting, being held March 1-5 in Washington, D.C. at the Walter E. Washington Convention Center.
The study results will be presented by Jill S. Waibel, MD, board-certified dermatologist practicing at the Miami Dermatology and Laser Institute and a Sebacia U.S. clinical trial investigator, and Arielle N.B. Kauvar, MD, board-certified dermatologist practicing at New York Laser & Skin Care.
In the real world, patients present to the dermatologist seeking acne treatment having a history of current or historical use of various acne medications. The most commonly prescribed first-line acne medication for mild to moderate acne is a topical retinoid. In Sebacia's EU registry study, patients were prescribed a 2-4 week course of topical retinoid + benzoyl peroxide (BPO) prior to treatment with Sebacia Microparticles to determine what effect the combination may have on long term acne outcomes and acne medication usage.
Details of the presentations that will include Sebacia 12-month real-world results:
Anthony Lando, Chief Executive Officer, said, "Our EU study reflects the real-world approach to treating acne and incorporates a short topical treatment prior to treatment with Sebacia Microparticles. We have seen very positive results out to 6 months with limited introduction of additional systemics and antibiotics, and look forward to sharing the durability of treatment out to 12-months with the dermatology community ahead of our planned launch in mid-2019."
About Sebacia
Sebacia, Inc. is a private medical device and aesthetics company focused on creating advanced topical therapies for the treatment of dermatological conditions, with a primary focus on a novel procedure-based acne treatment. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia Microparticles is cleared for use in the U.S. and in the EU, the two largest dermatology markets in the world. Sebacia is planning its U.S. commercial launch for mid-2019. In the EU, Sebacia Microparticles is sold in select markets. Investors in the company include Accuitive Medical Ventures, Domain Associates, Partners Innovation Fund, Salem Partners and Versant Ventures.
Sebacia, Inc. is located in Atlanta, Georgia. More information is available at www.sebacia.com or follow us at www.twitter.com/SebaciaNews and https://www.facebook.com/sebaciainc/.
Advertisement
The study results will be presented by Jill S. Waibel, MD, board-certified dermatologist practicing at the Miami Dermatology and Laser Institute and a Sebacia U.S. clinical trial investigator, and Arielle N.B. Kauvar, MD, board-certified dermatologist practicing at New York Laser & Skin Care.
Advertisement
In the real world, patients present to the dermatologist seeking acne treatment having a history of current or historical use of various acne medications. The most commonly prescribed first-line acne medication for mild to moderate acne is a topical retinoid. In Sebacia's EU registry study, patients were prescribed a 2-4 week course of topical retinoid + benzoyl peroxide (BPO) prior to treatment with Sebacia Microparticles to determine what effect the combination may have on long term acne outcomes and acne medication usage.
Details of the presentations that will include Sebacia 12-month real-world results:
- Session: F029 - Advances in Lasers and Light Sources: What's the Truth?
- Time: Friday, March 1; 3:30 - 5:30 p.m. EST
- Location: Ballroom C
- Session: S020 - Dermatologic Surgery: Cosmetic Tips and Pearls
- Time: Saturday, March 2; 9:00 a.m. - 12:00 p.m. EST
- Location: Ballroom A
- Session: S021 - What's New and What's True in Lasers
- Time: Saturday, March 2; 9:00 a.m. - 12:00 p.m. EST
- Location: Room 147B
Anthony Lando, Chief Executive Officer, said, "Our EU study reflects the real-world approach to treating acne and incorporates a short topical treatment prior to treatment with Sebacia Microparticles. We have seen very positive results out to 6 months with limited introduction of additional systemics and antibiotics, and look forward to sharing the durability of treatment out to 12-months with the dermatology community ahead of our planned launch in mid-2019."
About Sebacia
Sebacia, Inc. is a private medical device and aesthetics company focused on creating advanced topical therapies for the treatment of dermatological conditions, with a primary focus on a novel procedure-based acne treatment. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia Microparticles is cleared for use in the U.S. and in the EU, the two largest dermatology markets in the world. Sebacia is planning its U.S. commercial launch for mid-2019. In the EU, Sebacia Microparticles is sold in select markets. Investors in the company include Accuitive Medical Ventures, Domain Associates, Partners Innovation Fund, Salem Partners and Versant Ventures.
Sebacia, Inc. is located in Atlanta, Georgia. More information is available at www.sebacia.com or follow us at www.twitter.com/SebaciaNews and https://www.facebook.com/sebaciainc/.
View original content:http://www.prnewswire.com/news-releases/sebacia-to-present-new-12-month-durability-results-from-eu-real-world-acne-study-at-aad-annual-meeting-2019-300803313.html
SOURCE Sebacia, Inc.
